Most Read Articles
Pearl Toh, 2 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
5 days ago
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.

Female sex linked to poor survival outcomes after radical cystectomy for bladder cancer

19 Mar 2018

Women who undergo radical cystectomy for bladder cancer are more likely to have worse outcomes, including disease-free survival (DFS), cancer-specific survival (CSS) and overall survival (OS), compared with their male counterparts, a study reports.

Researchers conducted a systematic review and meta-analysis of studies evaluating gender-specific differences in DFS, CSS or OS following radical cystectomy in bladder cancer patients. Random effect meta-analysis, subgroup analyses, meta-influence and cumulative meta-analyses were used. Funnel plot and Egger´s test facilitated assessment of publication bias.

A total of 3,868 studies were identified during literature search, of which 59 were included in the analysis. There were 30 studies (n=38,321) that evaluated DFS, 44 studies (n=69,666) that evaluated CSS and 26 studies (n=30,039) that evaluated OS.

Pooled data revealed that DFS, CSS and OS were less favourable in female vs male patients, with respective hazard ratios of 1.16 (95 percent CI, 1.06–1.27; p=0.0018), 1.23 (1.15–1.31; p<0.001) and 1.08 (1.03–1.12; p=0.0004). Subgroup analyses confirmed worse DFS, CSS and OS in female patients in all strata.

Studies evaluating CSS showed publication bias (Egger´s test, p=0.0029). Correcting for publication bias via the trim and fill method yielded a corrected pooled HR estimate for CSS of 1.13 (1.05–1.21; p=0.0012).

The present data demonstrate gender-specific differences in DFS, CSS and OS following radical cystectomy in bladder cancer patients. Researchers pointed out that such difference might be explained by a multifactorial aetiology that included epidemiological differences, gender-specific healthcare discrepancies and hormonal influences.

Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
5 days ago
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.